Alectinib (CH5424802)是一种有效的ALK抑制剂,IC50为1.9 nM,对L1196M突变型敏感,作用于ALK比PF-02341066, NVP-TAE684和PHA-E429选择性高。;Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429An ATP-competitive inhibitor for ALK and L1196M.
体内研究:
Alectinib (0.2-20 mg/kg; oral administration; once daily; for 11 days; SCID or nude mice bearing NCI-H2228 cells) treatment can result in dose-dependent tumor growth inhibition (EC50 of 0.46 mg/kg) and tumor regression. At any dose level, no differences in body weight or gross signs of toxicity are observed.